AUS
NZ
UK
CA
USA
IND
Highlights
- Argent BioPharma expands cannabinoid epilepsy treatment in Slovenia
- Successful pilot leads to routine hospital use
- Multi-year regulatory collaboration drives clinical adoption
Argent BioPharma (ASX:RGT) has taken a significant step forward in European healthcare by commencing supply of its cannabinoid-based active pharmaceutical ingredient (API) to Slovenia’s largest hospital, marking a pivotal development in treating drug-resistant epilepsy. This expansion builds on the company’s earlier success in Ireland and other European territories, now translating into a real-world clinical application at the University Medical Centre Ljubljana (UMCL).
Following a successful pilot program, the cannabinoid API is being transitioned into routine use at UMCL’s paediatric clinic. This move enables neurologists to prescribe formulation protocols tailored to young patients with refractory epilepsy—one of the most complex neurological challenges in paediatric medicine.
Building a New Treatment Framework
The achievement is the result of a multi-year collaboration between Argent BioPharma, Slovenia’s Ministry of Health, and the Agency for Medicinal Products and Medical Devices (JAZMP). Throughout the partnership, Argent supplied extensive pre-clinical and clinical data supporting the efficacy and safety of its flagship CannEpil formulation.
CannEpil has already demonstrated practical clinical utility, helping refine dosage strategies, monitoring protocols, and logistical operations. These efforts played a vital role in shaping national policy, allowing hospital-based compounding of cannabinoid therapies for neurological disorders.
The API provided to Slovenia is produced by PHCANN International, a manufacturing partner holding EU-GMP certification. This ensures the quality and consistency of the formulation meets stringent European Pharmacopoeia standards—critical for gaining trust among prescribing clinicians.
A Regulatory Milestone with Broader Implications
The full-scale supply launch underscores Argent BioPharma’s expertise in navigating regulatory pathways and translating pilot initiatives into operational healthcare solutions. Through strategic alignment with health authorities and medical institutions, the company is redefining how cannabinoid-based therapies can be safely integrated into mainstream clinical practice.
Senior consultants at the University Medical Centre have voiced optimism about the new treatment option, highlighting its evidence-based framework. This marks a shift from experimental to structured cannabinoid therapy in hospital settings—particularly for complex epilepsy and encephalopathy cases in children and adolescents.
Though Argent BioPharma is not currently listed among the ASX 100 companies, its growing international footprint and regulatory advancements position it as a noteworthy innovator in the cannabinoid pharmaceuticals space.
This clinical rollout in Slovenia is more than a supply agreement—it represents a shift in therapeutic strategy, patient care standards, and the future of neuroimmune treatment options across Europe.
